Free Trial
NASDAQ:MRUS

Merus Q4 2023 Earnings Report

Merus logo
$65.84 -0.26 (-0.39%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$65.84 +0.00 (+0.01%)
As of 08/29/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus EPS Results

Actual EPS
-$1.09
Consensus EPS
-$0.71
Beat/Miss
Missed by -$0.38
One Year Ago EPS
N/A

Merus Revenue Results

Actual Revenue
$8.94 million
Expected Revenue
$10.43 million
Beat/Miss
Missed by -$1.49 million
YoY Revenue Growth
N/A

Merus Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, February 28, 2024
Conference Call Time
4:15PM ET

Upcoming Earnings

Merus' Q3 2025 earnings is scheduled for Thursday, October 30, 2025, with a conference call scheduled on Friday, October 31, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Merus Earnings Headlines

Merus to Present at the 2025 Wells Fargo Healthcare Conference
Merus (NASDAQ:MRUS) Coverage Initiated at Alliance Global Partners
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.tc pixel
See More Merus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Merus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Merus and other key companies, straight to your email.

About Merus

Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

View Merus Profile

More Earnings Resources from MarketBeat